corporate workshops
The Corporate Workshop sessions will be held on Sunday, September 28 from 12:30 PM - 2:30 PM . There is no charge to attend.
These sessions offer attendees the opportunity to hear about the latest products from the participating companies. Sessions will be available for all registered attendees to participate.
This is a "bring your own lunch" session. First 100 attendees who arrive at this session by 12:40 PM will receive a 10 USD Visa gift card as compensation for their lunch purchase.
12:30 PM - Cytek Biosciences
“Pairing Of Spectral Flow Cytometry And Machine Learning Based Decision Support System For Accurate Diagnosis Of Leukemia and Lymphoma”
Paul K. Wallace, Ph.D.
Professor Emeritus, Roswell Park Comprehensive Cancer Center
Flow cytometry is an essential methodology in the diagnosis and prognostication of leukemias and lymphomas (L&L). While flow cytometry data quality has improved with the increasing performance of instrumentation and the availability of novel fluorophores, the analysis of this data is complex, requiring significant training and time. Profiling >40 markers in a single tube is possible using spectral flow cytometry, but visualizing and analyzing these assays using standard bivariate plots is complex and inefficient in a clinical laboratory workflow. Here, we present an integrated solution for clinical workflows that covers the validation and implementation of laboratory developed tests (LDTs). The LDTs were developed as L&L diagnosis panels, consisting of reagents from multiple manufacturers, on the Cytek Northern Lights™ instrument, together with a novel machine learning algorithm and hematopathologist-developed clinical decision support software. This machine learning based method incorporates automatic fluidic abnormality detection, doublet detection, as well as red blood cell removal. Additionally, the machine learning based approach allows for automated adjustments of unmixing, decreasing technician time and effort. Overall, we demonstrate how the use of a machine learning based approach improves the clinical workflow by reducing the burden of data analysis on laboratory technicians and improving overall laboratory efficiency. Our work demonstrates that clinical decision support software can be implemented alongside spectral flow cytometry in routine diagnostics of L&L.
1:00 PM - BD Biosciences
- Discuss the clinical and technical principles behind high-sensitivity flow cytometry testing for PNH.
- Describe the main features of the DryFlowEx PNH High-Sensitivity Assay Kit, including its design, workflow, and diagnostic capabilities.
- Review the steps involved in validating and implementing a dry-reagent PNH assay in a clinical flow cytometry laboratory.
- Identify the practical advantages of using a dry-reagent kit in routine diagnostic workflows.
- Evaluate the impact of assay standardization on workflow efficiency, quality control, and result reproducibility.
“From Spectrum to Insight: Innovations Advancing High-Dimensional and Imaging Flow Cytometry”
Rodrigo Pestana Lopes, Pharm, MSc, PhD
Sr. Scientific Marketing Manager, BD Biosciences
This presentation explores how innovations in flow cytometry are enabling the generation of higher-parameter, more reproducible data. We begin by tracing the evolution from traditional polychromatic flow cytometry—dependent on discrete PMT filters for each fluorochrome—to spectral flow cytometry, which captures full-spectrum emission profiles across multiple lasers and detectors.
We then examine how this shift has catalyzed advances in fluorochrome development, focusing on improvements in brightness, spillover-spread, stability, and consistency. Key examples include BD HorizonTM Real dyes and their integration into multi-color dried reagent formats, which support greater experimental reproducibility and cross-instrument standardization.
Finally, we look ahead to the convergence of spectral flow cytometry and imaging—capabilities uniquely integrated in BD FACSDiscover™ instruments powered by BD SpectralFXTM and BD CellViewTM technologies. This platform enables extraction of image-derived parameters for subcellular classification, expanding the dimensionality and depth of spectral cytometric analysis for translational and preclinical research.
BD Flow Cytometers are Class I Laser products. For Research Use Only. Not for use in diagnostic or therapeutic procedures.
©2025 BD. All rights reserved. NPM-6939
1:30 PM - Beckman Coulter
“Integrating superRCA into the Clinical Workflow for Hematologic MRD Detection”
Wolfgang Kern, MD
MLL Munich Leukemia Laboratory
Diagnostics for hematopoietic neoplasms rely on a comprehensive, multimodal workflow that integrates phenotypic analyses—such as cytomorphology, flow cytometry, and histopathology—with genetic methods including chromosome banding, fluorescence in situ hybridization, PCR-based assays, quantitative PCR, and next-generation sequencing (NGS). Whole transcriptome and genome sequencing are emerging as additional tools, further enhancing diagnostic resolution. This integrated approach enables precise, patient-specific diagnoses that inform increasingly targeted therapies aligned with the principles of personalized medicine.
As these therapies achieve deeper remissions, monitoring measurable residual disease (MRD) has become critical for patient management. Conventional MRD techniques—flow cytometry and quantitative PCR—reach sensitivities of one cell per million but remain limited in their ability to detect certain genetic alterations. The superRCA assay (Rarity) introduces an innovative hybrid of genetic and flow cytometric technologies, delivering ultra-sensitive detection and addressing unmet needs in MRD assessment. This presentation will explore the assay’s technical principles, clinical utility, and potential to reshape MRD monitoring within established diagnostic workflows.
2:00 PM - Sysmex America
“From Validation to Routine Use: Lessons Learned from Implementing the DryFlowEx PNH High-Sensitivity Assay Kit”
Helena Varela de Araújo, MBA, SCYM(ASPCi)CM
Clinical Supervisor, Flow Cytometry
Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA
During this session, the speaker will share how DryFlowEx PNH High-Sensitivity Assay Kit was implemented in the clinical flow cytometry laboratory at Beth Israel Deaconess Medical Center (BIDMC) for the diagnosis of paroxysmal nocturnal hemoglobinuria (PNH). The DryFlowEx PNH kit is a CE-IVD–cleared dry-reagent panel that enables high-sensitivity detection of GPI-deficient erythrocytes and leukocytes in a simplified workflow. The presentation will cover the validation process and practical considerations for routine adoption. The speaker will highlight benefits observed including improved workflow efficiency, standardization, and compliance with current diagnostic guidelines. Challenges encountered during implementation and key lessons learned will also be discussed.